"Attendees at the prestigious AACR annual meeting are an important audience for Rosetta Genomics, and we are delighted that studies involving our microRNA-based diagnostic assays in kidney cancer and cancer of unknown or uncertain primary are being featured this year," said Kenneth A. Berlin , President and Chief Executive Officer of Rosetta Genomics.
"The classification of tumors into subtypes of renal cell cancer (RCC) has historically been less than definitive by histology, cytology and immunohistochemistry, particularly in the growing context of smaller, non-resection derived diagnostic specimens. Expanded clarity of RCC diagnosis through the availability of the miRview® kidney assay will help lead to improved rationalization and optimization of therapies both new and emerging," said Bob Wassman , M.D., Chief Medical Officer of Rosetta Genomics.
Regarding the second poster on CUP diagnosis by Rosetta's proprietary microRNA-based miRview® mets2 assay, he added, "Where clinical and immunohistochemical data are available, but uncertain, the resulting molecular diagnoses from our assay will generally fall within the range of possible cancers but more precisely and with no subjectivity, and will, with much higher confidence, identify one tumor type. There are also hallmark cases where unusual tumors of origin have actually been found only after molecular analysis, both of which are critical advances for these patients."<
|SOURCE Rosetta Genomics Ltd.|
Copyright©2012 PR Newswire.
All rights reserved